Meeting
2022 ASCO Annual Meeting
BRAF-targeted therapy for locally advanced ameloblastoma of the mandible: A potential neoadjuvant strategy.
Authors
Shirly Grynberg
Ella Lemelbaum Institute for Immuno Oncology and Melanoma, Sheba Medical Center, Ramat-Gan, Israel
Shirly Grynberg , Yael Steinberg , Nethanel Asher , Guy Ben-betzalel , Ronen Stoff , Gal Markel , Ronnie Shapira-Frommer , Jacob Schachter , Ariel Hirschhorn
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Other Developmental Therapeutics
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 3149)
DOI
10.1200/JCO.2022.40.16_suppl.3149
Abstract #
3149
Poster Bd #
140
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Short-term safety of adjuvant nivolumab therapy after neoadjuvant docetaxel plus cisplatin and 5-FU therapy for locally advanced esophageal squamous cell carcinoma.
First Author: Toshiharu Hirose
Poster
2017 ASCO Annual Meeting
Patterns of histologic response to neoadjuvant targeted therapy in patients with BRAF mutant melanoma.
First Author: Zeynep Eroglu
Poster
2023 ASCO Annual Meeting
Targeting AMP kinase in melanoma: A phase I trial of phenformin with dabrafenib/trametinib.
First Author: Paul B. Chapman
Poster
2022 ASCO Annual Meeting
Primary ipilimumab/nivolumab followed by adjuvant nivolumab in patients with locally advanced or oligometastatic melanoma: Update on outcome.
First Author: Emilia Cocorocchio